Latif Anne-Louise, McQuaker Grant, Parker Anne, Clark Andrew, Copland Mhairi
Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow, G61 1BD, UK.
Bone Marrow Transplant Unit, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 OYN, UK.
Leuk Res Rep. 2013 Jul 3;2(2):47-50. doi: 10.1016/j.lrr.2013.05.001. eCollection 2013.
Most patients now receiving a haematopoietic stem cell transplant (HSCT) for chronic myeloid leukaemia (CML) have been treated with first and second line TKIs pre-HSCT, raising concerns that these patients will have more resistant disease and accumulated greater toxicity from sequential lines of therapy, potentially compromising their outcome. We outline a series of 9 patients treated with imatinib then second generation TKIs for CML followed by HSCT and compare their outcomes with patients receiving imatinib-only pre-HSCT. Our case series demonstrates that second line and sequential tyrosine kinase inhibitors followed by HSCT is a safe and effective therapeutic approach for high risk CML.
目前，大多数因慢性髓性白血病（CML）接受造血干细胞移植（HSCT）的患者在HSCT前已接受一线和二线酪氨酸激酶抑制剂（TKI）治疗，这引发了人们的担忧，即这些患者的疾病可能更具耐药性，并且因序贯治疗而积累了更大的毒性，这可能会影响其治疗结果。我们概述了9例接受伊马替尼治疗，随后使用第二代TKI治疗CML，然后进行HSCT的患者，并将他们的治疗结果与HSCT前仅接受伊马替尼治疗的患者进行比较。我们的病例系列表明，二线及序贯酪氨酸激酶抑制剂治疗后再进行HSCT是治疗高危CML的一种安全有效的治疗方法。
